The 2nd Next Generation Cancer Vaccine Development Summit will focus on overcoming the translational and clinical challenges of therapeutic and prophylactic vaccines for oncology indications.

Attend our presentation

Is there a single “best” platform or will it be “fit to purpose”?

Time: 2:00 pm
Day: Pre-Conference Focus Day (August 16)

Speaker: Jeffrey Bockman, Executive Vice President of Commercial BioConsulting & Head of Oncology, Lumanity


  • Analyzing the advantages, disadvantages and comparisons of the DNA, Peptide, RNA, and Virus-based and other novel vaccine platforms
  • Harmonization of clinical outcomes and immune correlates
  • Considering if we can we get better at predictive animal models?
  • Questioning what other signals we need to provide to the immune system, either built into the vaccine or given concomitantly (checkpoints, costims, cytokines, innate immunity boosters, etc.)